Renal Anemia – Current Treatment – Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of chronic hypoxia, high mortality rates, and cardiovascular disease. Renal anemia nondialysis patients are initially treated with oral iron, followed by IV iron; ESAs are prescribed as third-line therapy. Dialysis patients usually receive IV iron therapy followed by ESAs. Several ESAs and iron supplements are available and have had varying degrees of commercial success. Key approved agents include Amgen’s Epogen, Janssen’s Procrit, Pfizer’s Retacrit, Amgen’s Aranesp, Roche / Chugai’s Mircera, and Akebia’s Auryxia. This report provides important insights into how these agents are used in the management of renal anemia and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed renal anemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed renal anemia patients?
- How have ESAs been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of renal anemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of renal anemia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Epogen / Procrit, Retacrit, Aranesp, Mircera, Auryxia, iron supplements
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
- Renal Anemia - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
- Treatment Algorithms CDA Renal Anemia US June 2023
- Treatment Algorithms CDA Renal Anemia 2023 Dashboard
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.